Valneva SE

Valneva announces publication of first Phase II data of tuberculosis vaccine candidate formulated with IC31® adjuvant

By Valneva SE
Published: Dec. 11, 2014, 10:44 p.m.· Tags: Vaccines, HIV coinfection, Scientific research

Clinical trial in HIV-infected adults showed good safety and immunogenicity

Read More →

Page 1 of 1 · Total posts: 1

1